Lupin receives approval for Phenylephrine and Ketorolac Intraocular Solution

Lupin has received approval for its Phenylephrine and Ketorolac Intraocular Solution from USFDA. The shares of the company however traded in red reacting to the news, on Wednesday.

Specifically, the United States Food and Drug Administration (USFDA) is for Phenylephrine and Ketorolac Intraocular Solution, 1%/0.3%. The company’s Phenylephrine and Ketorolac Intraocular Solution, 1%/0.3%, is the generic version of Omidria Intraocular Solution, 1%/0.3%, of Omeros Corporation (Omeros).

Phenylephrine and Ketorolac Intraocular Solution, 1%/0.3%, is added to an ocular irrigating solution used during cataract surgery or intraocular lens replacement. Phenylephrine and Ketorolac Intraocular Solution, 1%/0.3%, The said solutions had annual sales of approximately US$42.8 million in the US market, according to IQVIA MAT March 2019.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded and generic formulations, biotechnology products and APIs, globally.

On Wednesday, the shares of Lupin opened at Rs. 767.60 per share against Tuesday’s close of Rs.760.80. At closing hours, the stock was trading at Rs. 752.60, down by 1.08 per cent. Its intraday high was Rs.767.60 and intraday low was Rs. 747.20 per share on the BSE. The 52-week high stood at Rs. 986 and 52-week low was at Rs. 697.30 per share on the BSE.